Methods and compositions for inhibition of angiogenesis
US6114355A · kind A · utility
88Cited by
22References
112Claims
0Family size
Inventor
Key dates
| Filing date | Jul 30, 1998 |
| Grant date | Sep 5, 2000 |
| Priority date | — |
| Expiry date | Jul 30, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/535
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.